HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use MAGNESIUM SULFATE IN 5% DEXTROSE INJECTION safely and effectively. See full prescribing information for MAGNESIUM SULFATE IN 5% DEXTROSE INJECTION.
MAGNESIUM SULFATE IN DEXTROSE injection, for intravenous use
Initial U.S. Approval: 1941
INDICATIONS AND USAGE
DOSAGE AND ADMINISTRATION
DOSAGE FORMS AND STRENGTHS
Supplied in premixed single-dose bags: (3)
WARNINGS AND PRECAUTIONS
The most common adverse reactions are flushing, sweating, hypotension, depressed reflexes, flaccid paralysis, hypothermia, circulatory collapse, cardiac and central nervous system (CNS) depression proceeding to respiratory paralysis and hypocalcemia. Bradycardia, pulmonary edema, decreased respiratory rate, lethargy, sedation, somnolence, visual disturbances, and hypermagnesemia are also reported (6)
To report SUSPECTED ADVERSE REACTIONS, contact Hospira, Inc. at 1-800-441-4100 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
USE IN SPECIFIC POPULATIONS
Patients with severe renal impairment and/or a urine output less than 100 mL every 4 hours are at greater risk for increased magnesium concentrations that may lead to toxicity (8.6)
See 17 for PATIENT COUNSELING INFORMATION.
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.